Pharmacyclics Downgraded by Piper Jaffray to Neutral (PCYC)
Pharmacyclics (NASDAQ:PCYC) was downgraded by research analysts at Piper Jaffray from an “overweight” rating to a “neutral” rating in a report released on Friday, TheFlyOnTheWall.com reports.
PCYC has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Pharmacyclics in a research note on Monday. They now have a $93.00 price target on the stock. Separately, analysts at Ned Davis Research upgraded shares of Pharmacyclics from a “sell” rating to a “neutral” rating in a research note on Monday, April 21st. Finally, analysts at Morgan Stanley initiated coverage on shares of Pharmacyclics in a research note on Wednesday, March 26th. They set an “equal weight” rating and a $120.00 price target on the stock. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $151.60.
Shares of Pharmacyclics (NASDAQ:PCYC) traded down 9.35% during mid-day trading on Friday, hitting $86.305. The stock had a trading volume of 2,136,477 shares. Pharmacyclics has a one year low of $74.36 and a one year high of $154.89. The stock has a 50-day moving average of $103.3 and a 200-day moving average of $120.3. The company has a market cap of $6.455 billion and a P/E ratio of 109.44.
Pharmacyclics (NASDAQ:PCYC) last issued its quarterly earnings data on Friday, May 2nd. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.23. The company had revenue of $119.40 million for the quarter, compared to the consensus estimate of $105.38 million. During the same quarter in the previous year, the company posted ($0.73) earnings per share.
Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.